Nephrocare Health IPO Analyzed
Nephrocare Health, a company that provides dialysis treatments, is planning to sell shares to the public through an IPO. This means they’re raising money by offering shares for the first time. Investors can buy these shares, and the company hopes to get around ₹871 crore (about $105 million) to help grow their business.
Key Points
- Nephrocare Health seeks ₹871 crore through share sale.
- New dialysis clinics will receive ₹129.1 crore of funds.
- Existing debt will be paid off with ₹135.99 crore.
- Shares will trade on NSE and BSE starting December 17th.
- Minimum bid is 32 shares, investment starts at ₹14,720.
- Key investors include Investcorp and IIFL Capital Services.
The IPO will run from December 9th to December 12th, 2025. Investors can buy as little as 32 shares at once. A small investor would need to pay at least ₹14,720 to buy one lot.
Kfin Technologies is helping manage the sale of these shares. ICICI Securities, Ambit, IIFL Capital Services, and Nomura are also involved. The company wants to use the money to open new dialysis centers across India and pay off some of its debts.
Nephrocare Health’s business is doing well. In the last year, they made ₹755.81 crore in sales, which is a big increase from the previous year. Their profits have also grown significantly, from ₹35.13 crore to ₹67.09 crore.
“This IPO represents a significant step in Nephrocare Health’s journey to expand access to life-saving dialysis care across India.”
